Page last updated: 2024-12-11

morphine-6-glucuronide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

morphine-6-glucuronide: RN given refers to (5alpha,6alpha)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5360621
CHEMBL ID1330
CHEBI ID80581
SCHEMBL ID152647
MeSH IDM0108395

Synonyms (30)

Synonym
glucopyranosiduronic acid, 7,8-didehydro-4,5-alpha-epoxy-3-hydroxy-17-methylmorphinan-6-alpha-yl-, beta-d-
beta-d-glucopyranosiduronic acid, (5alpha,6alpha)-7,8-didehydro-4,5-epoxy-3-hydroxy-17-methylmorphinan-6-yl
morphine 6-glucuronide
morphine 6-beta-d-glucopyranosiduronide
morphine-6-glucuronide
20290-10-2
PDSP2_000436
chebi:80581 ,
morphine glucuronide
morphine 6-.beta.-d-glucuronide
CHEMBL1330
morphine glucuronide, (-)-
morphine 6-glucuronide(minor)
morphine glucuronide [inn]
unii-64y9kym60r
64y9kym60r ,
bdbm50370478
SCHEMBL152647
GNJCUHZOSOYIEC-GAROZEBRSA-N
DTXSID40174158
(2s,3s,4s,5r,6r)-3,4,5-trihydroxy-6-{[(1s,5r,13r,14s,17r)-10-hydroxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10,15-tetraen-14-yl]oxy}oxane-2-carboxylic acid
morphine 6-beta-d-glucuronide 1.0 mg/ml in water
morphine 6-beta-d-glucuronide 0.1 mg/ml in water
morfina 6beta- d-glucuronide
Q4303469
DB06409
(2s,3s,4s,5r,6r)-6-[[(4r,4ar,7s,7ar,12bs)-9-hydroxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid
morphine-glucuronide
morphine-6-beta-d-glucuronide, 1mg/ml in acetonitrile/water : 1/1
morphine-6-beta-d-glucuronide

Research Excerpts

Toxicity

The search for opioid analgesics with a better side-effect profile than morphine has led to a morphine metabolites, morphine-6-glucuronide (M6G) The active morphine metabolite may contribute to both the analgesia and the adverse effects observed during morphine therapy.

ExcerptReferenceRelevance
"The active morphine metabolite, morphine-6-glucuronide (M-6-G), may contribute to both the analgesia and the adverse effects observed during morphine (MOR) therapy."( Morphine-6-glucuronide concentrations and opioid-related side effects: a survey in cancer patients.
Foley, KM; Inturrisi, CE; Lapin, J; Portenoy, RK; Thaler, HT; Tiseo, PJ, 1995
)
2.02
"The newly developed controlled-release M suppository is safe and effective and may be a useful alternative for oral morphine administration in patients with cancer pain."( Clinical efficacy, safety and pharmacokinetics of a newly developed controlled release morphine sulphate suppository in patients with cancer pain.
Frijlink, HW; Meijler, WJ; Moolenaar, F; Proost, JH; Visser, J, 2000
)
0.31
"To investigate the effect of acute P-glycoprotein inhibition by the multidrug-resistance (MDR) modulator valspodar (SDZ PSC 833; PSC) on the pharmacokinetics, and potentially adverse pharmacodynamic effects of morphine, and its principal pharmacologically active metabolites, morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G)."( Effect of P-glycoprotein modulation on the clinical pharmacokinetics and adverse effects of morphine.
Ball, HA; Beglinger, C; Drewe, J; Haefeli, WE; Kemmler, A; Peng, B; Schächinger, H, 2000
)
0.48
"In a double-blind, three-way crossover study, the pharmacokinetic and potentially adverse pharmacodynamic effects (reaction time, transcutaneous PCO2, blood pressure) of morphine were compared with and without acute inhibition of P-glycoprotein by PSC."( Effect of P-glycoprotein modulation on the clinical pharmacokinetics and adverse effects of morphine.
Ball, HA; Beglinger, C; Drewe, J; Haefeli, WE; Kemmler, A; Peng, B; Schächinger, H, 2000
)
0.31
" PSC did not significantly affect the adverse events of morphine, as assessed by spontaneous reporting."( Effect of P-glycoprotein modulation on the clinical pharmacokinetics and adverse effects of morphine.
Ball, HA; Beglinger, C; Drewe, J; Haefeli, WE; Kemmler, A; Peng, B; Schächinger, H, 2000
)
0.31
" The search for opioid analgesics with a better side-effect profile than morphine has led to a morphine metabolites, morphine-6-glucuronide (M6G)."( Morphine-6-glucuronide: potency and safety compared with morphine.
Dahan, A; Morariu, A; van Dorp, EL, 2008
)
2
"The objectives of the current paper are to give an overview of the analgesic properties of M6G, assess the dose range at which it produces equianalgesia to morphine and explore its side-effect profile."( Morphine-6-glucuronide: potency and safety compared with morphine.
Dahan, A; Morariu, A; van Dorp, EL, 2008
)
1.79

Pharmacokinetics

To develop an integrated population pharmacokinetic model for heroin (diamorphine) and its pharmacodynamically active metabolites. To determine the pharmacokinetics of morphine, morphine-3-glucuronide (M3G) and morphine-6- glucuronides (M6G) in this population. To find clinically relevant parameters for dose individualisation.

ExcerptReferenceRelevance
" In BECF, the Tmax value for M6G was lower than for morphine, but the t1/2 beta values did not differ."( Analgesic response and plasma and brain extracellular fluid pharmacokinetics of morphine and morphine-6-beta-D-glucuronide in the rat.
Barjavel, MJ; Bhargava, HN; Plotkine, M; Sandouk, P; Scherrmann, JM; Stain, F, 1995
)
0.29
" The terminal half-life of normorphine was 23."( Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations.
Hasselström, J; Säwe, J, 1993
)
0.29
" Mean values of Cmax were 76 nmol/l (25-129) and 56 nmol/1 (15-140), respectively."( Rectal administration of morphine in children. Pharmacokinetic evaluation after a single-dose.
Beck, O; Boreus, LO; Lundeberg, S; Olsson, GL, 1996
)
0.29
"The rectal morphine hydrogel has pharmacokinetic properties which makes it a useful formulation for premedication and pain alleviation in paediatric patients."( Rectal administration of morphine in children. Pharmacokinetic evaluation after a single-dose.
Beck, O; Boreus, LO; Lundeberg, S; Olsson, GL, 1996
)
0.29
"60 ml min-1 kg-1, the elimination half-life was 11."( Morphine, morphine-6-glucuronide and morphine-3-glucuronide pharmacokinetics in newborn infants receiving diamorphine infusions.
Barker, DP; Barrett, DA; Pawula, M; Rutter, N; Shaw, PN, 1996
)
0.7
" This dosing regimen may be used in further pharmacodynamic studies to compare the analgesic effects of morphine and M-6-G."( Pharmacokinetics of morphine and its glucuronides after intravenous infusion of morphine and morphine-6-glucuronide in healthy volunteers.
Brune, K; Geisslinger, G; Kobal, G; Lötsch, J; Schmidt, N; Stockmann, A; Waibel, R, 1996
)
0.51
" The mean half-life of M6G after intravenous administration was 51."( Nasal administration of morphine-6-glucuronide in sheep--a pharmacokinetic study.
Barrett, DA; Davis, SS; Farraj, NF; Fisher, AN; Illum, L; Pawula, M; Shaw, PN, 1996
)
0.6
"A pharmacokinetic study was undertaken to compare the pharmacokinetics of morphine after an intravenous dose with the pharmacokinetics after a sublingual dose administered from an aerosol."( A pharmacokinetic study of sublingual aerosolized morphine in healthy volunteers.
Eden, OB; Joel, SP; Slevin, ML; Taylor, KM; Watson, NW, 1996
)
0.29
" There was no correlation between the time to peak analgesia and time to peak concentration for morphine or M-6-G."( A pharmacodynamic study of morphine and its glucuronide metabolites after single morphine dosing in cancer patients with pain.
Citron, M; Degaetano, C; Fanelli, C; Hoffman, M; Lehrer, M; Lesser, M; Meenan, G; Pascal, V; Smith, C; Xu, JC, 1997
)
0.3
" The present assay was applied to a pharmacokinetic study in rats after intraperitoneal administration of morphine."( High-performance liquid chromatography-mass spectrometry-mass spectrometry analysis of morphine and morphine metabolites and its application to a pharmacokinetic study in male Sprague-Dawley rats.
McErlane, KM; Ong, MC; Zheng, M, 1998
)
0.3
" Research is needed to establish whether morphine-6-beta-glucuronide qualifies as an analgesic; this study provides the pharmacokinetic bases for such studies."( Pharmacokinetics of morphine-6-glucuronide and its formation from morphine after intravenous administration.
Geisslinger, G; Kobal, G; Lötsch, J; Weiss, M, 1998
)
0.62
" Disposition parameters of morphine-6-beta-glucuronide and morphine were estimated by nonlinear regression, and basic pharmacokinetic parameters (clearance, volume of distribution at steady state, and mean disposition residence time) were derived."( Pharmacokinetics of morphine-6-glucuronide and its formation from morphine after intravenous administration.
Geisslinger, G; Kobal, G; Lötsch, J; Weiss, M, 1998
)
0.62
" The results of this study will serve as pharmacokinetic bases of future investigations of morphine-6-beta-glucuronide in human beings."( Pharmacokinetics of morphine-6-glucuronide and its formation from morphine after intravenous administration.
Geisslinger, G; Kobal, G; Lötsch, J; Weiss, M, 1998
)
0.62
" The current model of morphine and M6G pharmacokinetics after oral administration of morphine may serve as a pharmacokinetic basis for experiments evaluating the analgesic contribution of M6G with long-term oral dosing of morphine."( Pharmacokinetic modeling of M6G formation after oral administration of morphine in healthy volunteers.
Ahne, G; Geisslinger, G; Kobal, G; Lötsch, J; Weiss, M, 1999
)
0.3
" morphine, the concentrations of morphine, M6G and M3G and their pharmacokinetic parameters were similar to those we have observed previously, in other healthy volunteers (when standardized to nmol l- 1, for a 10 mg dose to a 70 kg subject)."( The pharmacokinetics of morphine and morphine glucuronide metabolites after subcutaneous bolus injection and subcutaneous infusion of morphine.
Currow, D; Joel, SP; McDonald, P; Slevin, ML; Stuart-Harris, R, 2000
)
0.31
" Blood for determination of plasma concentration of morphine (M) and its 3- and 6-glucuronides (M3G, M6G) was collected, and area under the plasma concentration-time curve (AUC)0-12 h, peak plasma concentration (Cmax), time to reach Cmax (tmax), and CO and C12 of M, M6G and M3G were determined on day 5 and day 10."( Clinical efficacy, safety and pharmacokinetics of a newly developed controlled release morphine sulphate suppository in patients with cancer pain.
Frijlink, HW; Meijler, WJ; Moolenaar, F; Proost, JH; Visser, J, 2000
)
0.31
" Apart from the C0 and C12, no significant differences in AUC0-12 h, tmax and Cmax of morphine between the rectal and oral route of administration were found."( Clinical efficacy, safety and pharmacokinetics of a newly developed controlled release morphine sulphate suppository in patients with cancer pain.
Frijlink, HW; Meijler, WJ; Moolenaar, F; Proost, JH; Visser, J, 2000
)
0.31
" Pharmacokinetic and pharmacodynamic analyses were performed simultaneously using mixed-effect models."( Pharmacokinetics and pharmacodynamics of inhaled versus intravenous morphine in healthy volunteers.
Connors, PM; Dershwitz, M; Morishige, RJ; Rosow, CE; Rubsamen, RM; Shafer, SL; Walsh, JL, 2000
)
0.31
"The pharmacokinetic data after intravenous administration were described by a three-exponent decay model preceded by a lag time."( Pharmacokinetics and pharmacodynamics of inhaled versus intravenous morphine in healthy volunteers.
Connors, PM; Dershwitz, M; Morishige, RJ; Rosow, CE; Rubsamen, RM; Shafer, SL; Walsh, JL, 2000
)
0.31
"To investigate the effect of acute P-glycoprotein inhibition by the multidrug-resistance (MDR) modulator valspodar (SDZ PSC 833; PSC) on the pharmacokinetics, and potentially adverse pharmacodynamic effects of morphine, and its principal pharmacologically active metabolites, morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G)."( Effect of P-glycoprotein modulation on the clinical pharmacokinetics and adverse effects of morphine.
Ball, HA; Beglinger, C; Drewe, J; Haefeli, WE; Kemmler, A; Peng, B; Schächinger, H, 2000
)
0.48
"In a double-blind, three-way crossover study, the pharmacokinetic and potentially adverse pharmacodynamic effects (reaction time, transcutaneous PCO2, blood pressure) of morphine were compared with and without acute inhibition of P-glycoprotein by PSC."( Effect of P-glycoprotein modulation on the clinical pharmacokinetics and adverse effects of morphine.
Ball, HA; Beglinger, C; Drewe, J; Haefeli, WE; Kemmler, A; Peng, B; Schächinger, H, 2000
)
0.31
" were unaffected there was a small but statistically significant increase in the AUC and Cmax of M3G (11."( Effect of P-glycoprotein modulation on the clinical pharmacokinetics and adverse effects of morphine.
Ball, HA; Beglinger, C; Drewe, J; Haefeli, WE; Kemmler, A; Peng, B; Schächinger, H, 2000
)
0.31
"Acute inhibition of P-glycoprotein by PSC in this setting does not affect the pharmacokinetic or safety-related pharmacodynamic profile of morphine in a clinically significant manner."( Effect of P-glycoprotein modulation on the clinical pharmacokinetics and adverse effects of morphine.
Ball, HA; Beglinger, C; Drewe, J; Haefeli, WE; Kemmler, A; Peng, B; Schächinger, H, 2000
)
0.31
" The half-life of M6G was 23+/-5 min in arterial blood, 26+/-10 min in venous blood and 58+/-17 min in brain ECF (P<0."( Blood-brain barrier transport and brain distribution of morphine-6-glucuronide in relation to the antinociceptive effect in rats--pharmacokinetic/pharmacodynamic modelling.
Bouw, MR; Hammarlund-Udenaes, M; Tunblad, K; Xie, R, 2001
)
0.56
" Pharmacokinetic (PK) parameters were calculated and bioequivalence assessed."( Pharmacokinetic evaluation of a sprinkle-dose regimen of a once-daily, extended-release morphine formulation.
Butler, J; Devane, J; Eliot, L; Loewen, G, 2002
)
0.31
" Cmax and total systemic exposure-based on AUC from time 0 to the last quantifiable concentration (AUC(last)) and AUC from time 0 to infinity (AUC(infinity))-were comparable between treatments."( Pharmacokinetic evaluation of a sprinkle-dose regimen of a once-daily, extended-release morphine formulation.
Butler, J; Devane, J; Eliot, L; Loewen, G, 2002
)
0.31
" The present study aimed to explore pharmacokinetic differences between morphine and morphine-glucuronides in mice after different routes of administration, and to investigate how possible differences were reflected in locomotor activity, a measure of psychostimulant properties."( Pharmacokinetic differences of morphine and morphine-glucuronides are reflected in locomotor activity.
Grung, M; Handal, M; Mørland, J; Ripel, A; Skurtveit, S, 2002
)
0.31
" Concentration time-course and interindividual variability of morphine (M), morphine-3-glucuronide (M3G) and morphine-6 glucuronide (M6G) were analysed using population pharmacokinetic modelling."( Pharmacokinetic modelling of morphine, morphine-3-glucuronide and morphine-6-glucuronide in plasma and cerebrospinal fluid of neurosurgical patients after short-term infusion of morphine.
Brockmöller, J; Freudenthaler, S; Gleiter, CH; Hofmann, U; Meineke, I; Mikus, G; Prange, HW; Schaeffeler, E; Schwab, M, 2002
)
0.55
"From the population pharmacokinetic model presented, CSF concentration profiles can be derived for M, M3G and M6G on the basis of dosing information and creatinine clearance without collecting CSF samples."( Pharmacokinetic modelling of morphine, morphine-3-glucuronide and morphine-6-glucuronide in plasma and cerebrospinal fluid of neurosurgical patients after short-term infusion of morphine.
Brockmöller, J; Freudenthaler, S; Gleiter, CH; Hofmann, U; Meineke, I; Mikus, G; Prange, HW; Schaeffeler, E; Schwab, M, 2002
)
0.55
" The data were analyzed using a population dose-driven approach, which uses a dose rate in function of time as input function driving the pharmacodynamics, and a population pharmacokinetic-pharmacodynamic (PK/PD) approach in which fixed pharmacokinetic parameter values from the literature were used as input function to the respiratory model."( Pharmacodynamic effect of morphine-6-glucuronide versus morphine on hypoxic and hypercapnic breathing in healthy volunteers.
Dahan, A; Olofsen, E; Romberg, R; Sarton, E; Teppema, L, 2003
)
0.62
" A population pharmacokinetic (inhibitory sigmoid Emax)-pharmacodynamic analysis was used to analyze M6G-induced changes in tolerated stimulus intensity."( Pharmacokinetic-pharmacodynamic modeling of morphine-6-glucuronide-induced analgesia in healthy volunteers: absence of sex differences.
Dahan, A; den Hartigh, J; Olofsen, E; Romberg, R; Sarton, E; Taschner, PE, 2004
)
0.58
" The volume of distribution increased exponentially with a maturation half-life of 26 days from 83 litres per 70 kg at birth; formation clearance to M3G and M6G increased with a maturation half-life of 88."( Developmental pharmacokinetics of morphine and its metabolites in neonates, infants and young children.
Anderson, BJ; Bouwmeester, NJ; Holford, NH; Tibboel, D, 2004
)
0.32
" Finally, we tested several pharmacokinetic models, assuming first-order or capacity-limited processes at each brain interface, to describe experimental morphine and M6G concentrations previously obtained in rat plasma and brain fluids."( Carrier-mediated processes at several rat brain interfaces determine the neuropharmacokinetics of morphine and morphine-6-beta-D-glucuronide.
Bourasset, F; Scherrmann, JM, 2006
)
0.33
"To develop an integrated population pharmacokinetic model for heroin (diamorphine) and its pharmacodynamically active metabolites 6-acetylmorphine, morphine, morphine-3-glucuronide and morphine-6-glucuronide."( Population pharmacokinetics of heroin and its major metabolites.
Beijnen, JH; Huitema, AD; Rook, EJ; van den Brink, W; van Ree, JM, 2006
)
0.52
" Pharmacokinetic findings were compared with those from a previous study in infants after noncardiac major surgery."( Morphine metabolite pharmacokinetics during venoarterial extra corporeal membrane oxygenation in neonates.
Anderson, BJ; Peters, JW; Simons, SH; Tibboel, D; Uges, DR, 2006
)
0.33
" Pharmacodynamic modeling revealed a sigmoidal relationship between plasma concentration and sedation score."( Pharmacokinetics and pharmacodynamics of morphine in llamas.
Chapman, PL; Hellyer, PW; KuKanich, B; Mama, KR; Papich, MG; Uhrig, SR; Wagner, AE, 2007
)
0.34
" A prolonged half-life was observed with IM injection."( Pharmacokinetics and pharmacodynamics of morphine in llamas.
Chapman, PL; Hellyer, PW; KuKanich, B; Mama, KR; Papich, MG; Uhrig, SR; Wagner, AE, 2007
)
0.34
"The pharmacokinetic profile of M6G after oral administration was confirmed and with the presence of M3G and morphine in plasma after oral administration of M6G, proof seems to be found of the constant and prolonged absorption of M6G."( Pharmacokinetics of morphine-6-glucuronide following oral administration in healthy volunteers.
Christrup, LL; Hansen, SH; Jensen, NH; Kristensen, K; Skram, U; Villesen, HH, 2007
)
0.66
" Pharmacokinetic and pharmacodynamic fitting was performed with the software NONMEM."( Morphine in postoperative patients: pharmacokinetics and pharmacodynamics of metabolites.
Butscher, K; Mazoit, JX; Samii, K, 2007
)
0.34
" The pharmacokinetic findings are compatible with a more rapid and extensive initial effect of IV morphine compared with IM."( Serum and cerebrospinal fluid morphine pharmacokinetics after single doses of intravenous and intramuscular morphine after hip replacement surgery.
Borchgrevink, PC; Dale, O; Klepstad, P; Nilsen, T; Thoner, J; Tveita, T, 2007
)
0.34
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" The elimination half-life was 140."( Pharmacokinetic and pharmacodynamic study of morphine and morphine 6-glucuronide after oral and intravenous administration of morphine in children with cancer.
Ghandforoush-Sattari, M; Hain, RD; Mashayekhi, SO; Routledge, PA, 2009
)
0.35
"In pharmacokinetic-pharmacodynamic modeling studies, venous plasma samples are sometimes used to derive pharmacodynamic model parameters."( Arterial and venous pharmacokinetics of morphine-6-glucuronide and impact of sample site on pharmacodynamic parameter estimates.
Aarts, L; Dahan, A; den Hartigh, J; Mooren, R; Olofsen, E; Sarton, E; Smith, T; van Dorp, E, 2010
)
0.63
" An extended pharmacokinetic model was constructed linking arterial and venous compartments."( Arterial and venous pharmacokinetics of morphine-6-glucuronide and impact of sample site on pharmacodynamic parameter estimates.
Aarts, L; Dahan, A; den Hartigh, J; Mooren, R; Olofsen, E; Sarton, E; Smith, T; van Dorp, E, 2010
)
0.63
" The extended pharmacokinetic model adequately described the data and consisted of 3 arterial compartments, 1 central venous compartment, and 1 peripheral venous compartment."( Arterial and venous pharmacokinetics of morphine-6-glucuronide and impact of sample site on pharmacodynamic parameter estimates.
Aarts, L; Dahan, A; den Hartigh, J; Mooren, R; Olofsen, E; Sarton, E; Smith, T; van Dorp, E, 2010
)
0.63
"Because of large arteriovenous differences in M6G plasma, concentration biases in pharmacodynamic model parameters will occur when linking venous concentration to effect, using a traditional effect-compartment model."( Arterial and venous pharmacokinetics of morphine-6-glucuronide and impact of sample site on pharmacodynamic parameter estimates.
Aarts, L; Dahan, A; den Hartigh, J; Mooren, R; Olofsen, E; Sarton, E; Smith, T; van Dorp, E, 2010
)
0.63
" In this study, the predictive performance of a previously published paediatric population pharmacokinetic model for morphine and its metabolites in children younger than 3 years (original model) is studied in new datasets that were not used to develop the original model."( Predictive performance of a recently developed population pharmacokinetic model for morphine and its metabolites in new datasets of (preterm) neonates, infants and children.
Choonara, I; Danhof, M; DeJongh, J; Knibbe, CA; Krekels, EH; Lynn, AM; Tibboel, D; van der Marel, CD; van Lingen, RA, 2011
)
0.37
" Basic observed versus predicted plots, normalized prediction distribution error analysis, model refitting, bootstrap analysis, subpopulation analysis and a literature comparison of clearance predictions were performed with the new datasets to evaluate the predictive performance of the original morphine pharmacokinetic model."( Predictive performance of a recently developed population pharmacokinetic model for morphine and its metabolites in new datasets of (preterm) neonates, infants and children.
Choonara, I; Danhof, M; DeJongh, J; Knibbe, CA; Krekels, EH; Lynn, AM; Tibboel, D; van der Marel, CD; van Lingen, RA, 2011
)
0.37
"The predictive value of the original morphine pharmacokinetic model is demonstrated in new datasets by the use of six different validation and evaluation tools."( Predictive performance of a recently developed population pharmacokinetic model for morphine and its metabolites in new datasets of (preterm) neonates, infants and children.
Choonara, I; Danhof, M; DeJongh, J; Knibbe, CA; Krekels, EH; Lynn, AM; Tibboel, D; van der Marel, CD; van Lingen, RA, 2011
)
0.37
" Al-though size and age often are considered primary covariates for morphine pharmacokinetic models, the impact of other factors important in personalizing care such as race and genetic variations on morphine disposition is not well documented."( Morphine clearance in children: does race or genetics matter?
Chidambaran, V; Esslinger, HR; Fukuda, T; Krekels, EH; Ngamprasertwong, P; Sadhasivam, S; Vinks, AA; Zhang, K,
)
0.13
"Genotype blinded clinical observational pharmacokinetic study."( Morphine clearance in children: does race or genetics matter?
Chidambaran, V; Esslinger, HR; Fukuda, T; Krekels, EH; Ngamprasertwong, P; Sadhasivam, S; Vinks, AA; Zhang, K,
)
0.13
"Morphine bolus for intraoperative analgesia in children and pharmacokinetic analyses in different races."( Morphine clearance in children: does race or genetics matter?
Chidambaran, V; Esslinger, HR; Fukuda, T; Krekels, EH; Ngamprasertwong, P; Sadhasivam, S; Vinks, AA; Zhang, K,
)
0.13
" A pharmacokinetic study was then carried out in three groups with CYP2D6*1/*1 (n=10), CYP2D6*1/*10 (n=10) and CYP2D6*10/*10 (n=9) genotypes by collecting serial blood samples for determination of plasma levels of codeine and its metabolites, morphine, morphine 3-glucuronide (M3G) and morphine 6-glucuronide (M6G) before and after a single 30-mg oral dose of codeine phosphate."( The impact of CYP2D6 polymorphisms on the pharmacokinetics of codeine and its metabolites in Mongolian Chinese subjects.
Guo, T; Lv, J; Wu, X; Yuan, L; Zuo, J, 2014
)
0.4
"No significant differences were observed in the pharmacokinetic parameters of codeine in the three genotype groups."( The impact of CYP2D6 polymorphisms on the pharmacokinetics of codeine and its metabolites in Mongolian Chinese subjects.
Guo, T; Lv, J; Wu, X; Yuan, L; Zuo, J, 2014
)
0.4
" Blood samples were collected up to 72 h postdrug administration, analyzed using LC-MS/MS and pharmacokinetic parameters determined."( Preliminary pharmacokinetics of morphine and its major metabolites following intravenous administration of four doses to horses.
Knych, HK; McKemie, DS; Steffey, EP, 2014
)
0.4
"The aim of this study was to evaluate the clinical pharmacokinetics of morphine (M) and their correlation with pharmacodynamic results (effective daily dose of M and side effects) during the M titration phase, in the management of chronic cancer pain."( Clinical pharmacokinetics of morphine and its metabolites during morphine dose titration for chronic cancer pain.
Allegri, M; De Gregori, M; De Gregori, S; Govoni, S; Minella, CE; Ranzani, GN; Regazzi, M; Tinelli, C, 2014
)
0.4
"This article presents the pharmacokinetic profiles of M and its metabolites: their concentration ratio could help clinicians to optimize individual therapies and tailor the dose to individual needs."( Clinical pharmacokinetics of morphine and its metabolites during morphine dose titration for chronic cancer pain.
Allegri, M; De Gregori, M; De Gregori, S; Govoni, S; Minella, CE; Ranzani, GN; Regazzi, M; Tinelli, C, 2014
)
0.4
"Ethanol and heroin are both depressant drugs on the central nervous system, and combined use is known to be dangerous due to pharmacodynamic interactions, leading to an even higher risk of respiratory depression and death."( Pharmacokinetic interactions between ethanol and heroin: a study on post-mortem cases.
Andersen, JM; Handal, M; Høiseth, G; Mørland, J; Thaulow, CH, 2014
)
0.4
" This pharmacokinetic interaction could further complicate the outcome after combined use of heroin and ethanol, in addition to the already well-known pharmacodynamic interactions."( Pharmacokinetic interactions between ethanol and heroin: a study on post-mortem cases.
Andersen, JM; Handal, M; Høiseth, G; Mørland, J; Thaulow, CH, 2014
)
0.4
" The aims were: (1) to develop a population pharmacokinetic model of liquid rectal morphine and morphine-6-glucoronide (M6G), (2) to simulate clinically relevant rectal doses of morphine and (3) to assess the tolerability and safety."( Population pharmacokinetics of morphine and morphine-6-glucuronide following rectal administration--a dose escalation study.
Brokjær, A; Christrup, LL; Dahan, A; Drewes, AM; Kreilgaard, M; Olesen, AE; Simonsson, US, 2015
)
0.68
"A population pharmacokinetic model of liquid rectal morphine and M6G was developed."( Population pharmacokinetics of morphine and morphine-6-glucuronide following rectal administration--a dose escalation study.
Brokjær, A; Christrup, LL; Dahan, A; Drewes, AM; Kreilgaard, M; Olesen, AE; Simonsson, US, 2015
)
0.68
" We aimed to develop a codeine pharmacokinetic pathway model for codeine and its metabolites that incorporates the effects of genetic polymorphisms."( CYP2D6 phenotype-specific codeine population pharmacokinetics.
Boston, RC; Daly Linares, AL; Fudin, J; Linares, OA; Schiesser, WE, 2015
)
0.42
" Simulations were also used to examine the impact of effect-site equilibration half-life on time course of response."( A review of morphine and morphine-6-glucuronide's pharmacokinetic-pharmacodynamic relationships in experimental and clinical pain.
Christrup, LL; Drewes, AM; Kreilgaard, M; Lund, TM; Olesen, AE; Sverrisdóttir, E, 2015
)
0.72
" To determine the pharmacokinetics of morphine, morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G) in this population, and to find clinically relevant parameters for dose individualisation, we performed a population pharmacokinetic analysis."( Pharmacokinetics of Morphine, Morphine-3-Glucuronide and Morphine-6-Glucuronide in Terminally Ill Adult Patients.
Baar, FP; de Winter, BC; Franken, LG; Koch, BC; Masman, AD; Mathot, RA; Tibboel, D; van Gelder, T, 2016
)
0.91
" Nonlinear mixed-effects modelling (NONMEM) was used to develop a population pharmacokinetic model and perform covariate analysis."( Pharmacokinetics of Morphine, Morphine-3-Glucuronide and Morphine-6-Glucuronide in Terminally Ill Adult Patients.
Baar, FP; de Winter, BC; Franken, LG; Koch, BC; Masman, AD; Mathot, RA; Tibboel, D; van Gelder, T, 2016
)
0.68
"The objective of the current study was to describe and characterize the pharmacokinetics and selected pharmacodynamic effects of morphine and its two major metabolites in horses following several doses of morphine."( Pharmacokinetics and selected pharmacodynamics of morphine and its active metabolites in horses after intravenous administration of four doses.
Hamamoto-Hardman, BD; Kass, P; Knych, HK; McKemie, DS; Steffey, EP; Weiner, D, 2019
)
0.51
" Our analysis demonstrates that body weight and postmenstrual age are relevant predictors of pharmacokinetic parameters of morphine and its metabolites."( Morphine Dose Optimization in Critically Ill Pediatric Patients With Acute Respiratory Failure: A Population Pharmacokinetic-Pharmacogenomic Study.
Benitez, GR; Bradfield, J; Curley, MAQ; Gastonguay, MR; Gastonguay, MS; Hakonarson, H; Moorthy, G; Prodell, J; Zane, NR; Zuppa, AF, 2019
)
0.51
" The simultaneous quantification of morphine, fentanyl and its metabolites via this simple and time- and cost-efficient method could be successfully applied to samples taken for pharmacokinetic evaluation (antemortem and postmortem) after a single dose of morphine or co-administration of morphine with other drugs (e."( Determination of Morphine, Fentanyl and Their Metabolites in Small Sample Volumes Using Liquid Chromatography Tandem Mass Spectrometry.
Gleba, J; Kim, J, 2020
)
0.56
" Passive BBB permeability of morphine and its active metabolite morphine-6-glucuronide (M6G) and their pharmacodynamic parameters were derived from experiments reported in literature."( Physiologically based pharmacokinetic/pharmacodynamic model for the prediction of morphine brain disposition and analgesia in adults and children.
de Wildt, SN; Koenderink, JB; Litjens, CHC; Mathijssen, RHJ; Russel, FGM; Verbeek, MM; Verscheijden, LFM, 2021
)
0.86
" Nebulized (NEB) morphine may represent an alternative for titration but pharmacokinetic (PK) properties of short nebulization using routine devices need evaluation."( Pharmacokinetic modeling of morphine and its glucuronides: Comparison of nebulization versus intravenous route in healthy volunteers.
Aubrun, F; Duflot, T; Joannidès, R; Lamoureux, F; Lvovschi, VE; Pereira, T; Tavolacci, MP, 2022
)
0.72

Compound-Compound Interactions

ExcerptReferenceRelevance
" If patients receive morphine and these drugs simultaneously, the drug-drug interaction may change the levels of morphine and these glucuronides, resulting in altered analgesic efficacy and the risk of side effects."( Morphine glucuronosyltransferase activity in human liver microsomes is inhibited by a variety of drugs that are co-administered with morphine.
Hara, Y; Miyamoto, K; Nakajima, M; Yokoi, T, 2007
)
0.34

Bioavailability

This study compared the bioavailability of MSER and its metabolites. Systemic bioavailability and peak plasma concentrations of morphine-6-glucuronide were significantly greater after oral morphine administration compared with the rectal route (AUC: M6G, 377)

ExcerptReferenceRelevance
" The bioavailability of free morphine and the 6-glucuronated active metabolite was comparable through the different routes."( Plasma morphine and morphine-6-glucuronide patterns in cancer patients after oral, subcutaneous, sublabial and rectal short-term administration.
Bianchi, M; Breda, M; Panerai, AE; Ripamonti, C; Ventafridda, V; Zecca, E, 1991
)
0.6
" Morphine bioavailability and morphine glucuronide production were not altered."( Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucuronide.
Joel, S; Osborne, R; Slevin, M; Trew, D, 1990
)
0.48
" The mean oral bioavailability was 101% (95% CI 56-147)."( The metabolism and bioavailability of morphine in patients with severe liver cirrhosis.
Eriksson, S; Hasselström, J; Persson, A; Rane, A; Säwe, J; Svensson, JO, 1990
)
0.28
"The bioavailability of oral controlled release morphine tablets (MST, Napp Laboratories) and oral morphine sulphate in aqueous solution (MSS) was compared in 10 patients with advanced cancer."( Relative bioavailability of controlled release morphine tablets (MST continus) in cancer patients.
A-Omar, O; Aherne, GW; Hanks, GW; Hoskin, PJ; Johnston, A; Poulain, P; Turner, P; Walker, VA, 1988
)
0.27
" In accordance with previous results marked interindividual differences were seen in the kinetics of morphine; the oral bioavailability varied between 30 and 69% and the systemic plasma clearance between 18."( Oral morphine in cancer patients: in vivo kinetics and in vitro hepatic glucuronidation.
Kager, L; Rane, A; Säwe, J; Svensson Eng, JO, 1985
)
0.27
" The absolute bioavailability of morphine in both IR and in CR tablets was, 32%, and the relative bioavailability of the CR tablet versus the IR tablets was 103% (91-115%, 95% confidence interval)."( Plasma concentrations of morphine, morphine-3-glucuronide, and morphine-6-glucuronide after intravenous and oral administration to healthy volunteers: relationship to nonanalgesic actions.
Höglund, P; Persson, C; Westerling, D, 1995
)
0.53
" This study shows that administration of a suppository with 30 mg nicomorphine gives an excellent absolute bioavailability of morphine and its metabolites of 88%."( Rectal administration of nicomorphine in patients improves biological availability of morphine and its glucuronide conjugates.
Booij, LH; Dirksen, R; Koopman-Kimenai, PM; Vree, TB, 1994
)
0.29
" Systemic bioavailability and peak plasma concentrations of morphine-6-glucuronide and morphine-3-glucuronide were significantly greater after oral morphine administration compared with the rectal route (AUC: M6G, 377."( Disposition of morphine and its glucuronide metabolites after oral and rectal administration: evidence of route specificity.
Babul, N; Darke, AC, 1993
)
0.53
"8 L/kg and oral bioavailability was 29."( Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations.
Hasselström, J; Säwe, J, 1993
)
0.29
"29), suggesting it is directly related to the absorption rate of nicomorphine."( The bioavailability of intramuscularly administered nicomorphine (Vilan) with its metabolites and their glucuronide conjugates in surgical patients.
Booij, LH; Dirksen, R; Koopman-Kimenai, PM; Vree, TB, 1995
)
0.29
" This investigation was carried out to evaluate the bioavailability of a recent sustained-release (SR) formulation of morphine sulphate (30 mg), Skenan, consisted of capsules, relative to a recognized product, Moscontin which is a matrix tablet SR form."( Study of the bioequivalence of two controlled-release formulations of morphine.
Bourget, P; Lesne-Hulin, A; Quinquis-Desmaris, V, 1995
)
0.29
"The mean rectal bioavailability of morphine was 35% (range 18-59) after hydrogel administration and 27% (range 6-93) after the solution."( Rectal administration of morphine in children. Pharmacokinetic evaluation after a single-dose.
Beck, O; Boreus, LO; Lundeberg, S; Olsson, GL, 1996
)
0.29
" The bioavailability of M6G in the chitosan formulation was found to be 31."( Nasal administration of morphine-6-glucuronide in sheep--a pharmacokinetic study.
Barrett, DA; Davis, SS; Farraj, NF; Fisher, AN; Illum, L; Pawula, M; Shaw, PN, 1996
)
0.6
") bioavailability of the sublingual aerosol morphine was 19."( A pharmacokinetic study of sublingual aerosolized morphine in healthy volunteers.
Eden, OB; Joel, SP; Slevin, ML; Taylor, KM; Watson, NW, 1996
)
0.29
" Of this, 42+/-8% passed through the liver, resulting in an oral bioavailability of morphine of 34+/-9%."( Pharmacokinetic modeling of M6G formation after oral administration of morphine in healthy volunteers.
Ahne, G; Geisslinger, G; Kobal, G; Lötsch, J; Weiss, M, 1999
)
0.3
" The authors found that, with administration by inhalation, the total bioavailability was 59%, of which 43% was absorbed almost instantaneously and 57% was absorbed with a half-life of 18 min."( Pharmacokinetics and pharmacodynamics of inhaled versus intravenous morphine in healthy volunteers.
Connors, PM; Dershwitz, M; Morishige, RJ; Rosow, CE; Rubsamen, RM; Shafer, SL; Walsh, JL, 2000
)
0.31
" Morphine bioavailability after such administration is 59% of the dose loaded into the dosage form."( Pharmacokinetics and pharmacodynamics of inhaled versus intravenous morphine in healthy volunteers.
Connors, PM; Dershwitz, M; Morishige, RJ; Rosow, CE; Rubsamen, RM; Shafer, SL; Walsh, JL, 2000
)
0.31
" The variation in plasma morphine concentrations was higher than that of oxycodone, consistent with the lower bioavailability of morphine."( Morphine or oxycodone in cancer pain?
Heiskanen, TE; Kalso, EA; Ruismäki, PM; Seppälä, TA, 2000
)
0.31
"This study compared the bioavailability of MSER and its metabolites morphine-3-glucuronide and morphine-6-glucuronide after administration of MSER in a sprinkle-dose regimen relative to an intact capsule swallowed whole."( Pharmacokinetic evaluation of a sprinkle-dose regimen of a once-daily, extended-release morphine formulation.
Butler, J; Devane, J; Eliot, L; Loewen, G, 2002
)
0.53
" Oral bioavailability of M6G and the fraction of M6G deglucuronidated to morphine were estimated from areas under the plasma-concentration vs."( Verapamil decreases glucuronidase activity in the gut.
Geisslinger, G; Kroemer, HK; Lötsch, J; Sperker, B, 2002
)
0.31
" Intraperitoneal administration of morphine reduced the bioavailability compared to intravenous and subcutaneous administration, but not so for morphine-glucuronides."( Pharmacokinetic differences of morphine and morphine-glucuronides are reflected in locomotor activity.
Grung, M; Handal, M; Mørland, J; Ripel, A; Skurtveit, S, 2002
)
0.31
") administration to SOP rabbits was almost the same as that in normal rabbits, suggesting that an increase in the rate of absorption of morphine in SOP rabbits was not due to inflammation at the absorption site caused by operation, but probably due to its increased solubility in loose stools."( Bioavailability of a morphine suppository is increased after intracolostomal administration in colostoma-constructed rabbits.
Fujimoto, S; Kintsuji, S; Nagai, K; Nagasawa, K; Nakanishi, H, 2003
)
0.32
" In this study, we investigated the bioavailability of topically applied morphine to cutaneous ulcers."( The bioavailability of morphine applied topically to cutaneous ulcers.
Joel, SP; Ribeiro, MD; Zeppetella, G, 2004
)
0.32
" Despite the promise, M6G is not an ideal drug because bioavailability is low and hydrolysis occurs in the gut."( Dynamic medicinal chemistry in the elaboration of morphine-6-glucuronide analogs.
Cashman, JR; MacDougall, JM, 2005
)
0.58
" Oral bioavailability was 5% as determined from naïve-averaged analysis."( Pharmacokinetics of morphine and plasma concentrations of morphine-6-glucuronide following morphine administration to dogs.
KuKanich, B; Lascelles, BD; Papich, MG, 2005
)
0.57
"The bioavailability of inhaled heroin was estimated to be 53% (95% CI 43."( Population pharmacokinetics of heroin and its major metabolites.
Beijnen, JH; Huitema, AD; Rook, EJ; van den Brink, W; van Ree, JM, 2006
)
0.33
" Moreover, the intravenous titration option used in the study provided a clean collection of pharmacokinetic surrogate data of morphine along with its metabolites without the issue of absorption and/or oral bioavailability setback if morphine was given by oral route."( Do we have clarity on the therapeutic levels of morphine and its metabolites: seeking answers for the dilemma?
Srinivas, NR, 2013
)
0.39
"6h, clearance 78 L/h [relative standard error (RSE) 12%] and absolute bioavailability 24% (RSE 11%)."( Population pharmacokinetics of morphine and morphine-6-glucuronide following rectal administration--a dose escalation study.
Brokjær, A; Christrup, LL; Dahan, A; Drewes, AM; Kreilgaard, M; Olesen, AE; Simonsson, US, 2015
)
0.68
" Here we evaluate the relative bioavailability of morphine ARER and extended-release morphine."( Relative Oral Bioavailability of an Abuse-deterrent, Extended-release Formulation of Morphine Versus Extended-release Morphine: A 2-period, Single-dose, Randomized Crossover Study in Healthy Subjects.
Aigner, S; Kinzler, ER; Pantaleon, C, 2018
)
0.48
"This single-dose, 2-treatment, 2-period, 2-sequence, randomized crossover study in healthy adult subjects compared the relative bioavailability of morphine ARER 100 mg to that of ER morphine 100 mg in the fasted condition."( Relative Oral Bioavailability of an Abuse-deterrent, Extended-release Formulation of Morphine Versus Extended-release Morphine: A 2-period, Single-dose, Randomized Crossover Study in Healthy Subjects.
Aigner, S; Kinzler, ER; Pantaleon, C, 2018
)
0.48

Dosage Studied

The effects of novel dosing forms on morphine metabolism and distribution were examined. Estimated ED50 from the dose-response curves showed about a 30 times more potent antinociceptive effect of morphine-6-glucuronide compared with morphine.

ExcerptRelevanceReference
" Peak concentrations were observed within 1 h of dosage and concentrations then declined biexponentially."( Plasma morphine-3-glucuronide, morphine-6-glucuronide and morphine concentrations in patients receiving long-term epidural morphine.
Bradley, JP; Brown, AM; Cavenagh, JD; Ravenscroft, PJ; Schneider, JJ, 1992
)
0.57
" To understand better the relationship between morphine and M-6-G in cancer patients receiving chronic therapy, we employed high performance liquid chromatography with electrochemical detection to measure: (1) morphine and M-6-G plasma concentrations following discontinuation of dosing in 2 patients, one receiving oral therapy and the other an intravenous infusion; (2) morphine and M-6-G concentrations in random blood samples taken at apparent steady state from 8 patients, 7 with normal renal function and 1 with mild renal insufficiency, who were receiving continuous morphine infusions; and (3) morphine and M-6-G concentrations in random blood samples taken over a period of weeks from 4 patients, 2 with stable and 2 with declining renal function."( Plasma morphine and morphine-6-glucuronide during chronic morphine therapy for cancer pain: plasma profiles, steady-state concentrations and the consequences of renal failure.
Adelhardt, J; Cerbone, DF; Foley, KM; Inturrisi, CE; Khan, E; Layman, M; Portenoy, RK; Stulman, J, 1991
)
0.6
" The dose-response curve for minute ventilation was steeper for morphine-6-glucuronide than for morphine."( Antinociceptive and ventilatory effects of the morphine metabolites: morphine-6-glucuronide and morphine-3-glucuronide.
Björkman, R; Gong, QL; Hedner, J; Hedner, T; Nordberg, G, 1991
)
0.75
" The quantitative significance of the active metabolite morphine-6-glucuronide was assessed, and the effects of novel dosing forms on morphine metabolism and distribution were examined."( Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucuronide.
Joel, S; Osborne, R; Slevin, M; Trew, D, 1990
)
0.73
" These findings call for cautious dosing of oral and intravenous morphine in patients with severe end stage liver disease."( The metabolism and bioavailability of morphine in patients with severe liver cirrhosis.
Eriksson, S; Hasselström, J; Persson, A; Rane, A; Säwe, J; Svensson, JO, 1990
)
0.28
" Subsequent dose-response studies across a somewhat lower dose range using equimolar doses of morphine and M6G (3-80 mumoles/kg) found that both drugs significantly increased locomotor activity beginning at 20 mumoles/kg."( Morphine-6-glucuronide: a potent stimulator of locomotor activity in mice.
Alkana, RL; Jones, BL; Mørland, J; Palomares, ML, 1994
)
1.73
" Estimated ED50 from the dose-response curves for morphine and morphine-6-glucuronide showed about a 30 times more potent antinociceptive effect of morphine-6-glucuronide compared with morphine."( Intrathecal morphine-3-glucuronide does not antagonize spinal antinociception by morphine or morphine-6-glucuronide in rats.
Kalso, E; Rosenberg, PH; Suzuki, N, 1993
)
0.75
" A randomized, placebo-controlled study comparing the time-action, dose-response and potency of the respiratory effects of M6G to morphine was done using a nonanesthetized neonatal guinea pig model and a noninvasive computerized plethysmograph technique."( Morphine-6-beta-D-glucuronide respiratory pharmacodynamics in the neonatal guinea pig.
Murphey, LJ; Olsen, GD, 1994
)
0.29
"The plasma concentrations and renal clearance values of morphine, morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G) were determined in 11 adult cancer patients maintained on a long term oral morphine dosage (10 to 100mg every 4h)."( Plasma concentrations and renal clearance of morphine, morphine-3-glucuronide and morphine-6-glucuronide in cancer patients receiving morphine.
Bochner, F; Cleary, JF; Danz, C; Milne, RW; Nation, RL; Olweny, C; Somogyi, AA; Tsirgiotis, P; van Crugten, J, 1993
)
0.73
" This information must be considered above all as a dosage adjustment tool enabling use of the two forms by application of a correction factor of the order of 15% when prescribing Skenan in comparison with Moscontin."( Study of the bioequivalence of two controlled-release formulations of morphine.
Bourget, P; Lesne-Hulin, A; Quinquis-Desmaris, V, 1995
)
0.29
" The AUC0-24 ratios were similar to those following oral and rectal dosing in other studies involving cancer patients."( Rectal controlled-release morphine: plasma levels of morphine and its metabolites following the rectal administration of MST Continus 100 mg.
Campbell, WI, 1996
)
0.29
" The dose-response curve for M6G was shifted to the right by prior administration of M3G."( Lack of morphine-6-glucuronide antinociception after morphine treatment. Is morphine-3-glucuronide involved?
Cabanes, CG; Faura, CC; Horga, JF; Olaso, JM, 1996
)
0.73
" We also examined tolerance on these analgesic systems by using a daily morphine injection paradigm which shifts the dose-response curve for systemic morphine approximately 2-fold after 5 days."( Peripheral morphine analgesia: synergy with central sites and a target of morphine tolerance.
Jain, S; Kolesnikov, YA; Pasternak, GW; Wilson, R, 1996
)
0.29
"The pharmacokinetics of morphine-6-glucuronide (M6G) after both intravenous dosing and nasal administration were studied in sheep."( Nasal administration of morphine-6-glucuronide in sheep--a pharmacokinetic study.
Barrett, DA; Davis, SS; Farraj, NF; Fisher, AN; Illum, L; Pawula, M; Shaw, PN, 1996
)
0.91
" In dose-response studies, 3-methoxynaltrexone (2."( 3-Methoxynaltrexone, a selective heroin/morphine-6beta-glucuronide antagonist.
Brown, GP; Chang, A; King, MA; Leventhal, L; Pasternak, GW; Rossi, GC; Yang, K, 1997
)
0.3
"Under steady-state conditions in the first dosing interval, mean maximum plasma concentrations for morphine were 19."( Bioequivalence study of two morphine extended release formulations after multiple dosing in healthy volunteers.
Blume, HH; Crawford, F; Elze, M; Evers, G; Heinrich-Nols, J; Larsimont, V; Lee, LS; Schug, BS, 1999
)
0.3
" Simulation of effect-site concentrations of M6G indicated that after multiple oral dosing of morphine in patients with normal liver and renal function, M6G might reach concentrations two times greater than that of morphine."( Pharmacokinetic modeling of M6G formation after oral administration of morphine in healthy volunteers.
Ahne, G; Geisslinger, G; Kobal, G; Lötsch, J; Weiss, M, 1999
)
0.3
" The current model of morphine and M6G pharmacokinetics after oral administration of morphine may serve as a pharmacokinetic basis for experiments evaluating the analgesic contribution of M6G with long-term oral dosing of morphine."( Pharmacokinetic modeling of M6G formation after oral administration of morphine in healthy volunteers.
Ahne, G; Geisslinger, G; Kobal, G; Lötsch, J; Weiss, M, 1999
)
0.3
" Morphine dosage must therefore be carefully controlled in patients with renal failure."( [Morphine poisoning in chronic kidney failure. Morphine-6-glucuronide as a pharmacologically active morphine metabolite].
Caduff, B; Dubs, A; Wiedemeier, P, 1999
)
0.56
" Inclusion of a fixed dose of 3-O-methylnaltrexone significantly shifted the analgesic dose-response curves for 6-acetylmorphine and heroin without altering the morphine dose-response curves."( Antagonism of heroin and morphine self-administration in rats by the morphine-6beta-glucuronide antagonist 3-O-methylnaltrexone.
Izzo, E; King, M; Koob, GF; Pasternak, GW; Walker, JR, 1999
)
0.3
" Morphine bioavailability after such administration is 59% of the dose loaded into the dosage form."( Pharmacokinetics and pharmacodynamics of inhaled versus intravenous morphine in healthy volunteers.
Connors, PM; Dershwitz, M; Morishige, RJ; Rosow, CE; Rubsamen, RM; Shafer, SL; Walsh, JL, 2000
)
0.31
"This was a randomized, open-label, single-dose, crossover study, with a 7-day washout period between the 2 dosing days."( Pharmacokinetic evaluation of a sprinkle-dose regimen of a once-daily, extended-release morphine formulation.
Butler, J; Devane, J; Eliot, L; Loewen, G, 2002
)
0.31
"From the population pharmacokinetic model presented, CSF concentration profiles can be derived for M, M3G and M6G on the basis of dosing information and creatinine clearance without collecting CSF samples."( Pharmacokinetic modelling of morphine, morphine-3-glucuronide and morphine-6-glucuronide in plasma and cerebrospinal fluid of neurosurgical patients after short-term infusion of morphine.
Brockmöller, J; Freudenthaler, S; Gleiter, CH; Hofmann, U; Meineke, I; Mikus, G; Prange, HW; Schaeffeler, E; Schwab, M, 2002
)
0.55
" As a positive control, morphine was infused at a dosage that definitely produced CNS effects."( Peripheral opioid analgesia in experimental human pain models.
Burian, M; Geisslinger, G; Lötsch, J; Meier, S; Schmidt, H; Tegeder, I, 2003
)
0.32
"Comparisons of spontaneous mutant C57BL/6-Mc1r(e/e) mice to C57BL/6 wildtype mice, followed by a gene dosage study of pain and morphine-6-glucuronide (M6G) analgesia in humans with MC1R variants."( Melanocortin-1 receptor gene variants affect pain and mu-opioid analgesia in mice and humans.
Bijl, H; Dahan, A; Fillingim, RB; Kaplan, L; Mogil, JS; Ritchie, J; Romberg, RR; Sarton, EY; Smith, SB; Strasburg, K; Wallace, MR, 2005
)
0.53
" For pain patients who have reduced renal function such as those in palliative care, most opioids used for chronic pain treatment should be administered at reduced dosages, with increased dosage intervals, or not at all because of the risk of accumulation of the parent compound or its metabolites."( Renal impairment: a challenge for opioid treatment? The role of buprenorphine.
Böger, RH, 2006
)
0.33
"To determine the dose-response effect of intravenous morphine-6-glucuronide (M6G) on acute postoperative pain."( A randomized, double-blind, placebo-controlled pilot study of IV morphine-6-glucuronide for postoperative pain relief after knee replacement surgery.
Binning, A; Dahan, A; Hollander, J; Kruit, M; Romberg, R; Smith, T; van Dorp, E,
)
0.62
"A total of 170 patients were dosed with study medication."( Efficacy and safety of morphine-6-glucuronide (M6G) for postoperative pain relief: a randomized, double-blind study.
Binning, AR; Dahan, A; Smith, TW, 2009
)
0.66
"Forty-five opium-dependent Thai subjects were allocated to three dosing groups (6."( Flexible dosing of tincture of opium in the management of opioid withdrawal: pharmacokinetics and pharmacodynamics.
Abadi, RM; Ali, R; Jittiwutikarn, J; Larsen, M; Somogyi, AA; White, JM, 2008
)
0.35
"The management of opioid withdrawal can be achieved, with minimal adverse effects, by using flexible dosing of TOP."( Flexible dosing of tincture of opium in the management of opioid withdrawal: pharmacokinetics and pharmacodynamics.
Abadi, RM; Ali, R; Jittiwutikarn, J; Larsen, M; Somogyi, AA; White, JM, 2008
)
0.35
"Model validation procedures are crucial when models are to be used to develop new dosing algorithms."( Predictive performance of a recently developed population pharmacokinetic model for morphine and its metabolites in new datasets of (preterm) neonates, infants and children.
Choonara, I; Danhof, M; DeJongh, J; Knibbe, CA; Krekels, EH; Lynn, AM; Tibboel, D; van der Marel, CD; van Lingen, RA, 2011
)
0.37
" It is herewith justified to undertake a proof-of-principle approach in the development of rational dosing recommendations - namely, performing a prospective clinical trial in which the model-based dosing algorithm is clinically evaluated."( Predictive performance of a recently developed population pharmacokinetic model for morphine and its metabolites in new datasets of (preterm) neonates, infants and children.
Choonara, I; Danhof, M; DeJongh, J; Knibbe, CA; Krekels, EH; Lynn, AM; Tibboel, D; van der Marel, CD; van Lingen, RA, 2011
)
0.37
" For constipation, M6G, fentanyl and buprenorphine were full agonists, oxycodone was a partial agonist, morphine produced a bell-shaped dose-response curve, whereas DPDPE and U69,593 were inactive."( In vivo profiling of seven common opioids for antinociception, constipation and respiratory depression: no two opioids have the same profile.
Kuo, A; Meutermans, W; Smith, MT; Wyse, BD, 2015
)
0.42
" Our study suggests that pharmacogenetics for personalized dosing might be most effectively advanced by studying the interplay between pharmacogenetics, population pharmacokinetics, and clinical pharmacokinetics."( CYP2D6 phenotype-specific codeine population pharmacokinetics.
Boston, RC; Daly Linares, AL; Fudin, J; Linares, OA; Schiesser, WE, 2015
)
0.42
"Morphine is a widely used opioid for treatment of moderate to severe pain, but large interindividual variability in patient response and no clear guidance on how to optimise morphine dosage regimen complicates treatment strategy for clinicians."( A review of morphine and morphine-6-glucuronide's pharmacokinetic-pharmacodynamic relationships in experimental and clinical pain.
Christrup, LL; Drewes, AM; Kreilgaard, M; Lund, TM; Olesen, AE; Sverrisdóttir, E, 2015
)
0.72
"Morphine dosing can be challenging in terminally ill adult patients due to the heterogeneous nature of the population and the difficulty of accurately assessing pain during sedation."( Pharmacokinetics of Morphine, Morphine-3-Glucuronide and Morphine-6-Glucuronide in Terminally Ill Adult Patients.
Baar, FP; de Winter, BC; Franken, LG; Koch, BC; Masman, AD; Mathot, RA; Tibboel, D; van Gelder, T, 2016
)
0.68
"5 hours before dosing and 12 hours after dosing, all subjects received a 50-mg oral naltrexone tablet to minimize opioid-related side effects."( Relative Oral Bioavailability of an Abuse-deterrent, Extended-release Formulation of Morphine Versus Extended-release Morphine: A 2-period, Single-dose, Randomized Crossover Study in Healthy Subjects.
Aigner, S; Kinzler, ER; Pantaleon, C, 2018
)
0.48
" As to date species-specific pharmacokinetics data are not available for epidural morphine, the dosing regimen is usually established on the basis of clinical reports and personal experience."( Morphine plasmatic concentration in a pregnant mare and its foal after long term epidural administration.
Birras, J; Diez Bernal, S; Mirra, A; Spadavecchia, C, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
morphinane alkaloidAn isoquinoline alkaloid based on a morphinan skeleton and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (4)

PathwayProteinsCompounds
Morphine Action Pathway4716
Morphine Metabolism Pathway176
Codeine and Morphine Pathway, Pharmacokinetics165
Codeine and morphine metabolism07

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Mu-type opioid receptorHomo sapiens (human)Ki0.03800.00000.419710.0000AID1202692; AID238500
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Mas-related G-protein coupled receptor member X2Homo sapiens (human)EC50 (µMol)19.00000.14003.73818.9000AID1802709
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (26)

Processvia Protein(s)Taxonomy
lipid metabolic processUDP-glucuronosyltransferase 2B7Homo sapiens (human)
xenobiotic metabolic processUDP-glucuronosyltransferase 2B7Homo sapiens (human)
androgen metabolic processUDP-glucuronosyltransferase 2B7Homo sapiens (human)
estrogen metabolic processUDP-glucuronosyltransferase 2B7Homo sapiens (human)
cellular glucuronidationUDP-glucuronosyltransferase 2B7Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMu-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
sensory perceptionMu-type opioid receptorHomo sapiens (human)
negative regulation of cell population proliferationMu-type opioid receptorHomo sapiens (human)
sensory perception of painMu-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
behavioral response to ethanolMu-type opioid receptorHomo sapiens (human)
positive regulation of neurogenesisMu-type opioid receptorHomo sapiens (human)
negative regulation of Wnt protein secretionMu-type opioid receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeMu-type opioid receptorHomo sapiens (human)
calcium ion transmembrane transportMu-type opioid receptorHomo sapiens (human)
cellular response to morphineMu-type opioid receptorHomo sapiens (human)
regulation of cellular response to stressMu-type opioid receptorHomo sapiens (human)
regulation of NMDA receptor activityMu-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayMu-type opioid receptorHomo sapiens (human)
sensory perception of painMas-related G-protein coupled receptor member X2Homo sapiens (human)
sleepMas-related G-protein coupled receptor member X2Homo sapiens (human)
positive regulation of cytokinesisMas-related G-protein coupled receptor member X2Homo sapiens (human)
mast cell degranulationMas-related G-protein coupled receptor member X2Homo sapiens (human)
mast cell activationMas-related G-protein coupled receptor member X2Homo sapiens (human)
G protein-coupled receptor signaling pathwayMas-related G-protein coupled receptor member X2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (11)

Processvia Protein(s)Taxonomy
retinoic acid bindingUDP-glucuronosyltransferase 2B7Homo sapiens (human)
glucuronosyltransferase activityUDP-glucuronosyltransferase 2B7Homo sapiens (human)
G-protein alpha-subunit bindingMu-type opioid receptorHomo sapiens (human)
G protein-coupled receptor activityMu-type opioid receptorHomo sapiens (human)
beta-endorphin receptor activityMu-type opioid receptorHomo sapiens (human)
voltage-gated calcium channel activityMu-type opioid receptorHomo sapiens (human)
protein bindingMu-type opioid receptorHomo sapiens (human)
morphine receptor activityMu-type opioid receptorHomo sapiens (human)
G-protein beta-subunit bindingMu-type opioid receptorHomo sapiens (human)
neuropeptide bindingMu-type opioid receptorHomo sapiens (human)
G protein-coupled receptor activityMas-related G-protein coupled receptor member X2Homo sapiens (human)
neuropeptide bindingMas-related G-protein coupled receptor member X2Homo sapiens (human)
mast cell secretagogue receptor activityMas-related G-protein coupled receptor member X2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (11)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membraneUDP-glucuronosyltransferase 2B7Homo sapiens (human)
membraneUDP-glucuronosyltransferase 2B7Homo sapiens (human)
endosomeMu-type opioid receptorHomo sapiens (human)
endoplasmic reticulumMu-type opioid receptorHomo sapiens (human)
Golgi apparatusMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
axonMu-type opioid receptorHomo sapiens (human)
dendriteMu-type opioid receptorHomo sapiens (human)
perikaryonMu-type opioid receptorHomo sapiens (human)
synapseMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
neuron projectionMu-type opioid receptorHomo sapiens (human)
membraneMas-related G-protein coupled receptor member X2Homo sapiens (human)
plasma membraneMas-related G-protein coupled receptor member X2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (76)

Assay IDTitleYearJournalArticle
AID240216Stimulation of [35S]GTPcS binding against recombinant human opioid receptor delta 12005Bioorganic & medicinal chemistry letters, Mar-15, Volume: 15, Issue:6
Synthesis and in vitro biological evaluation of a carbon glycoside analogue of morphine-6-glucuronide.
AID1701337Ratio of drug level in brain to plasma in mouse
AID25837Log P of Cation (Chloroform water medium); LogP1996Journal of medicinal chemistry, Oct-25, Volume: 39, Issue:22
Octanol-, chloroform-, and propylene glycol dipelargonat-water partitioning of morphine-6-glucuronide and other related opiates.
AID1209583Unbound drug partitioning coefficient, Kp of the compound assessed as ratio of unbound concentration in Sprague-Dawley rat brain to unbound concentration in plasma2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
AID25844Log P of anion(PGDP water medium)1996Journal of medicinal chemistry, Oct-25, Volume: 39, Issue:22
Octanol-, chloroform-, and propylene glycol dipelargonat-water partitioning of morphine-6-glucuronide and other related opiates.
AID25835Log D of compound; LogD at pH 7.41996Journal of medicinal chemistry, Oct-25, Volume: 39, Issue:22
Octanol-, chloroform-, and propylene glycol dipelargonat-water partitioning of morphine-6-glucuronide and other related opiates.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID240071Stimulation of [35S]GTP-gamma-S, binding at Opioid receptor kappa 12004Journal of medicinal chemistry, Nov-04, Volume: 47, Issue:23
Design, chemical synthesis, and biological evaluation of thiosaccharide analogues of morphine- and codeine-6-glucuronide.
AID615258Analgesic activity in sc dosed Swiss mouse assessed as assessed as thermal-stimulus induced tail flick latency after 60 mins2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Synthesis and biological evaluation of analogues of M6G.
AID152212mu-2 receptor binding affinity in rat brain by 3H [d-Ala2, (N-Me)Phe4, Gly5-ol] enkephalin displacement.2003Bioorganic & medicinal chemistry letters, Mar-24, Volume: 13, Issue:6
Structure-activity relationships of some opiate glycosides.
AID239231Inhibition of [3H]U-69593 binding to Opioid receptor kappa 12004Journal of medicinal chemistry, Nov-04, Volume: 47, Issue:23
Design, chemical synthesis, and biological evaluation of thiosaccharide analogues of morphine- and codeine-6-glucuronide.
AID28939Liphophilic induce(log ki) value was measured in octanol-water system at PH 81991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
Morphine 6-glucuronide and morphine 3-glucuronide as molecular chameleons with unexpected lipophilicity.
AID25839Log P of Zwitterion1996Journal of medicinal chemistry, Oct-25, Volume: 39, Issue:22
Octanol-, chloroform-, and propylene glycol dipelargonat-water partitioning of morphine-6-glucuronide and other related opiates.
AID240431Maximum efficacy for [35S]GTP-gamma-S, binding to Opioid receptor delta 12004Journal of medicinal chemistry, Nov-04, Volume: 47, Issue:23
Design, chemical synthesis, and biological evaluation of thiosaccharide analogues of morphine- and codeine-6-glucuronide.
AID1202695AUC in rat interstitial fluid at 10 mg/kg, sc by transcortical microdialysis2015Journal of medicinal chemistry, Mar-26, Volume: 58, Issue:6
CNS drug design: balancing physicochemical properties for optimal brain exposure.
AID624640Drug glucuronidation reaction catalyzed by human recombinant UGT2B72005Pharmacology & therapeutics, Apr, Volume: 106, Issue:1
UDP-glucuronosyltransferases and clinical drug-drug interactions.
AID28934Liphophilic induce(log ki) value was measured in octanol-water system at PH 31991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
Morphine 6-glucuronide and morphine 3-glucuronide as molecular chameleons with unexpected lipophilicity.
AID354315Antinociceptive activity in Sprague-Dawley rat at 1 mg/kg, ip after 30 mins by tail flick test2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Synthesis, conformation, and biological characterization of a sugar derivative of morphine that is a potent, long-lasting, and nontolerant antinociceptive.
AID25845Sugar COOH pKa of compound1996Journal of medicinal chemistry, Oct-25, Volume: 39, Issue:22
Octanol-, chloroform-, and propylene glycol dipelargonat-water partitioning of morphine-6-glucuronide and other related opiates.
AID28937Liphophilic induce(log ki) value was measured in octanol-water system at PH 61991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
Morphine 6-glucuronide and morphine 3-glucuronide as molecular chameleons with unexpected lipophilicity.
AID25846Amine pKa of compound1996Journal of medicinal chemistry, Oct-25, Volume: 39, Issue:22
Octanol-, chloroform-, and propylene glycol dipelargonat-water partitioning of morphine-6-glucuronide and other related opiates.
AID240196Stimulation of [35S]GTPcS binding against recombinant human opioid receptor mu 12005Bioorganic & medicinal chemistry letters, Mar-15, Volume: 15, Issue:6
Synthesis and in vitro biological evaluation of a carbon glycoside analogue of morphine-6-glucuronide.
AID1202700Ratio of unbound drug in brain to plasma in rat2015Journal of medicinal chemistry, Mar-26, Volume: 58, Issue:6
CNS drug design: balancing physicochemical properties for optimal brain exposure.
AID240070Stimulation of [35S]GTP-gamma-S, binding at Opioid receptor delta 12004Journal of medicinal chemistry, Nov-04, Volume: 47, Issue:23
Design, chemical synthesis, and biological evaluation of thiosaccharide analogues of morphine- and codeine-6-glucuronide.
AID239152Inhibition of [3H]DAMGO binding to Opioid receptor mu 12004Journal of medicinal chemistry, Nov-04, Volume: 47, Issue:23
Design, chemical synthesis, and biological evaluation of thiosaccharide analogues of morphine- and codeine-6-glucuronide.
AID238573Inhibition of [3H]U-69593 binding to recombinant human Opioid receptor kappa 12005Bioorganic & medicinal chemistry letters, Mar-15, Volume: 15, Issue:6
Synthesis and in vitro biological evaluation of a carbon glycoside analogue of morphine-6-glucuronide.
AID25843Log P of anion (Chloroform water medium)1996Journal of medicinal chemistry, Oct-25, Volume: 39, Issue:22
Octanol-, chloroform-, and propylene glycol dipelargonat-water partitioning of morphine-6-glucuronide and other related opiates.
AID25850Phenolic pKa of compound1996Journal of medicinal chemistry, Oct-25, Volume: 39, Issue:22
Octanol-, chloroform-, and propylene glycol dipelargonat-water partitioning of morphine-6-glucuronide and other related opiates.
AID240442Percentage stimulation of [35S]-GTPcS binding compared to relevant control2005Bioorganic & medicinal chemistry letters, Mar-15, Volume: 15, Issue:6
Synthesis and in vitro biological evaluation of a carbon glycoside analogue of morphine-6-glucuronide.
AID25833Log D of compound (Chloroform water medium)1996Journal of medicinal chemistry, Oct-25, Volume: 39, Issue:22
Octanol-, chloroform-, and propylene glycol dipelargonat-water partitioning of morphine-6-glucuronide and other related opiates.
AID25842Log P of anion1996Journal of medicinal chemistry, Oct-25, Volume: 39, Issue:22
Octanol-, chloroform-, and propylene glycol dipelargonat-water partitioning of morphine-6-glucuronide and other related opiates.
AID604025Unbound CSF to plasma concentration ratio in Sprague-Dawley rat administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID238500Inhibition of [3H]-DAMGO binding to recombinant human Opioid receptor mu 12005Bioorganic & medicinal chemistry letters, Mar-15, Volume: 15, Issue:6
Synthesis and in vitro biological evaluation of a carbon glycoside analogue of morphine-6-glucuronide.
AID244176Receptor selectivity ratio for Opioid receptors delta 1 and mu 12005Bioorganic & medicinal chemistry letters, Mar-15, Volume: 15, Issue:6
Synthesis and in vitro biological evaluation of a carbon glycoside analogue of morphine-6-glucuronide.
AID135327BBB penetration classification2000Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11
Predicting blood-brain barrier permeation from three-dimensional molecular structure.
AID244109Ratio of Ki for Opioid receptors delta 1 and mu 12004Journal of medicinal chemistry, Nov-04, Volume: 47, Issue:23
Design, chemical synthesis, and biological evaluation of thiosaccharide analogues of morphine- and codeine-6-glucuronide.
AID240217Stimulation of [35S]GTPcS binding against recombinant human opioid receptor kappa 12005Bioorganic & medicinal chemistry letters, Mar-15, Volume: 15, Issue:6
Synthesis and in vitro biological evaluation of a carbon glycoside analogue of morphine-6-glucuronide.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID781326pKa (acid-base dissociation constant) as determined by Avdeef ref: DOI: 10.1002/047145026X2014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID604022Fraction unbound in Sprague-Dawley rat plasma administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID1209582Unbound volume of distribution in Sprague-Dawley rat brain slices at 100 nM after 5 hrs2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
AID349682Antinociceptive activity in Sprague-Dawley rat assessed as effect on mechanical nociceptive threshold at 1 to 5 mg/kg, ip after 30 mins by paw pressure test2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Synthesis, conformation, and biological characterization of a sugar derivative of morphine that is a potent, long-lasting, and nontolerant antinociceptive.
AID25836Log P of Cation1996Journal of medicinal chemistry, Oct-25, Volume: 39, Issue:22
Octanol-, chloroform-, and propylene glycol dipelargonat-water partitioning of morphine-6-glucuronide and other related opiates.
AID240066Stimulation of [35S]GTP-gamma-S, binding at Opioid receptor mu 12004Journal of medicinal chemistry, Nov-04, Volume: 47, Issue:23
Design, chemical synthesis, and biological evaluation of thiosaccharide analogues of morphine- and codeine-6-glucuronide.
AID25838Log P of Cation (PGDP water medium)1996Journal of medicinal chemistry, Oct-25, Volume: 39, Issue:22
Octanol-, chloroform-, and propylene glycol dipelargonat-water partitioning of morphine-6-glucuronide and other related opiates.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID108561Area under the antinociceptive effect time curve after 2 mg/kg administration in mice.2003Bioorganic & medicinal chemistry letters, Mar-24, Volume: 13, Issue:6
Structure-activity relationships of some opiate glycosides.
AID1202693AUC in rat brain at 10 mg/kg, sc2015Journal of medicinal chemistry, Mar-26, Volume: 58, Issue:6
CNS drug design: balancing physicochemical properties for optimal brain exposure.
AID604023Ratio of total drug level in brain to plasma in Sprague-Dawley rat administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID604026Unbound CSF to plasma concentration ratio in human2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID29346pKa value of the compound1991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
Morphine 6-glucuronide and morphine 3-glucuronide as molecular chameleons with unexpected lipophilicity.
AID604024Unbound brain to plasma concentration ratio in Sprague-Dawley rat administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID28936Liphophilic induce(log ki) value was measured in octanol-water system at PH 51991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
Morphine 6-glucuronide and morphine 3-glucuronide as molecular chameleons with unexpected lipophilicity.
AID1209581Fraction unbound in Sprague-Dawley rat brain homogenates at 5 uM by equilibrium dialysis analysis2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
AID1202694Ratio of drug uptake in brain to plasma in rat2015Journal of medicinal chemistry, Mar-26, Volume: 58, Issue:6
CNS drug design: balancing physicochemical properties for optimal brain exposure.
AID240441Maximum efficacy for [35S]GTP-gamma-S, binding to Opioid receptor kappa 1; no activity2004Journal of medicinal chemistry, Nov-04, Volume: 47, Issue:23
Design, chemical synthesis, and biological evaluation of thiosaccharide analogues of morphine- and codeine-6-glucuronide.
AID240458Percentage stimulation of [35S]GTPcS binding compared to relevant control; ND=Not detectable activity2005Bioorganic & medicinal chemistry letters, Mar-15, Volume: 15, Issue:6
Synthesis and in vitro biological evaluation of a carbon glycoside analogue of morphine-6-glucuronide.
AID238564Inhibition of [3H]DPDPE binding to recombinant human Opioid receptor delta 12005Bioorganic & medicinal chemistry letters, Mar-15, Volume: 15, Issue:6
Synthesis and in vitro biological evaluation of a carbon glycoside analogue of morphine-6-glucuronide.
AID28935Liphophilic induce(log ki) value was measured in octanol-water system at PH 41991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
Morphine 6-glucuronide and morphine 3-glucuronide as molecular chameleons with unexpected lipophilicity.
AID239209Inhibition of [3H]DPDPE binding to Opioid receptor delta 12004Journal of medicinal chemistry, Nov-04, Volume: 47, Issue:23
Design, chemical synthesis, and biological evaluation of thiosaccharide analogues of morphine- and codeine-6-glucuronide.
AID354314Antinociceptive activity in Sprague-Dawley rat at 5 mg/kg, ip after 30 mins by tail flick test2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Synthesis, conformation, and biological characterization of a sugar derivative of morphine that is a potent, long-lasting, and nontolerant antinociceptive.
AID151912mu-1 receptor binding affinity in rat brain by 3H [d-Ala2, d-Leu5] enkephalin displacement.2003Bioorganic & medicinal chemistry letters, Mar-24, Volume: 13, Issue:6
Structure-activity relationships of some opiate glycosides.
AID25841Log P of Zwitterion(PGDP water medium)1996Journal of medicinal chemistry, Oct-25, Volume: 39, Issue:22
Octanol-, chloroform-, and propylene glycol dipelargonat-water partitioning of morphine-6-glucuronide and other related opiates.
AID244110Ratio of Ki for Opioid receptors kappa 1 and mu 12004Journal of medicinal chemistry, Nov-04, Volume: 47, Issue:23
Design, chemical synthesis, and biological evaluation of thiosaccharide analogues of morphine- and codeine-6-glucuronide.
AID25840Log P of Zwitterion (Chloroform water medium)1996Journal of medicinal chemistry, Oct-25, Volume: 39, Issue:22
Octanol-, chloroform-, and propylene glycol dipelargonat-water partitioning of morphine-6-glucuronide and other related opiates.
AID108682Area under the antinociceptive effect time curve after 4 mg/kg administration in mice.2003Bioorganic & medicinal chemistry letters, Mar-24, Volume: 13, Issue:6
Structure-activity relationships of some opiate glycosides.
AID28938Liphophilic induce(log ki) value was measured in octanol-water system at PH 71991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
Morphine 6-glucuronide and morphine 3-glucuronide as molecular chameleons with unexpected lipophilicity.
AID604020Unbound drug concentration in Sprague-Dawley rat plasma administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID240430Maximum efficacy for [35S]GTP-gamma-S, binding to Opioid receptor mu 12004Journal of medicinal chemistry, Nov-04, Volume: 47, Issue:23
Design, chemical synthesis, and biological evaluation of thiosaccharide analogues of morphine- and codeine-6-glucuronide.
AID1209593Dissociation constant, pKa of the acidic compound by capillary electrophoresis-mass spectrometry analysis2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
AID25834Log D of compound (PGDP water medium)1996Journal of medicinal chemistry, Oct-25, Volume: 39, Issue:22
Octanol-, chloroform-, and propylene glycol dipelargonat-water partitioning of morphine-6-glucuronide and other related opiates.
AID1209592Dissociation constant, pKa of the basic compound by capillary electrophoresis-mass spectrometry analysis2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1202692Displacement of [3H]naloxone from MOR (unknown origin) expressed in human 293T cells2015Journal of medicinal chemistry, Mar-26, Volume: 58, Issue:6
CNS drug design: balancing physicochemical properties for optimal brain exposure.
AID604021Unbound volume of distribution in Sprague-Dawley rat brain measured per gram of brain tissue administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr b2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID1802709PRESTO-Tango Assay from Article 10.1038/nchembio.2334: \\In silico design of novel probes for the atypical opioid receptor MRGPRX2.\\2017Nature chemical biology, 05, Volume: 13, Issue:5
In silico design of novel probes for the atypical opioid receptor MRGPRX2.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (528)

TimeframeStudies, This Drug (%)All Drugs %
pre-199035 (6.63)18.7374
1990's206 (39.02)18.2507
2000's196 (37.12)29.6817
2010's79 (14.96)24.3611
2020's12 (2.27)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 35.38

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index35.38 (24.57)
Research Supply Index6.46 (2.92)
Research Growth Index5.10 (4.65)
Search Engine Demand Index53.49 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (35.38)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials90 (16.36%)5.53%
Reviews31 (5.64%)6.00%
Case Studies20 (3.64%)4.05%
Observational3 (0.55%)0.25%
Other406 (73.82%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]